<?xml version="1.0" encoding="UTF-8"?>
<ref id="B171-marinedrugs-17-00374" class="ref">
 <label class="label">171.</label>
 <element-citation publication-type="journal" class="element-citation">
  <person-group person-group-type="author" class="person-group">
   <name class="name">
    <surname class="surname">Ridker</surname>
    <given-names class="given-names">P.M.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Howard</surname>
    <given-names class="given-names">C.P.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Walter</surname>
    <given-names class="given-names">V.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Everett</surname>
    <given-names class="given-names">B.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Libby</surname>
    <given-names class="given-names">P.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Hensen</surname>
    <given-names class="given-names">J.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Thuren</surname>
    <given-names class="given-names">T.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Group</surname>
    <given-names class="given-names">C.P.I.</given-names>
   </name>
  </person-group>
  <article-title class="article-title">Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: A phase IIb randomized, placebo-controlled trial</article-title>
  <source class="source">Circulation</source>
  <year class="year">2012</year>
  <volume class="volume">126</volume>
  <fpage class="fpage">2739</fpage>
  <lpage class="lpage">2748</lpage>
  <pub-id pub-id-type="doi" class="pub-id">10.1161/CIRCULATIONAHA.112.122556</pub-id>
  <pub-id pub-id-type="pmid" class="pub-id">23129601</pub-id>
 </element-citation>
</ref>
